Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Meltzer Website

Paul S. Meltzer, M.D., Ph.D.

Selected Publications

1)  Gindin Y, Valenzuela MS, Aladjem MI, Meltzer PS, Bilke S.
A chromatin structure-based model accurately predicts DNA replication timing in human cells.
Mol. Syst. Biol. 10: 722, 2014.
2)  Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, Lee C, Varanasi L, Yang Y, Martinez LA, Luo J, Ambs S, Sharma S, Wakefield LM, Meltzer PS, Lal A.
A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.
Oncogene. [Epub ahead of print], 2014.
3)  Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yang Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer PS, Lal A.
A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster.
Mol. Cell. Biol. 34: 533-50, 2014.
4)  Gao R, Das BB, Chatterjee R, Abaan OD, Agama K, Matuo R, Vinson C, Meltzer PS, Pommier Y.
Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel.
DNA Repair (Amst.). 13: 1-9, 2014.
5)  Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, Davis S, Edelman DC, Merino MJ, He M, Zhang L, Meltzer PS, Kebebew E.
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.
J. Clin. Endocrinol. Metab. 99: E329-37, 2014.
6)  Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Nat. Genet. 46: 8-10, 2014.
7)  Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S.
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
J. Clin. Invest. 124: 398-412, 2014.
8)  Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD.
NUP98-PHF23 Is a Chromatin-Modifying Oncoprotein That Causes a Wide Array of Leukemias Sensitive to Inhibition of PHD Histone Reader Function.
Cancer Discov. 4: 564-77, 2014.
9)  Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton P, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Janeway KA, Weigel BJ, Randall RL, Meltzer PS, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Uren A, Patel S, Trent JM, Savage SA, Mirabello L, Reinke D, Barkauskas DA, Smith MA, Bernstein ML, Kirsch DG, Krailo MD.
Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma.
Clin. Cancer Res. [Epub ahead of print], 2014.
10)  Trucco MM, Awad O, Wilky BA, Goldstein SD, Huang R, Walker RL, Shah P, Katuri V, Gul N, Zhu YJ, McCarthy EF, Paz-Priel I, Meltzer PS, Austin CP, Xia M, Loeb DM.
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-?B signaling in chordoma biology.
PLoS ONE. 8: e79950, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 5/8/2014.